Page last updated: 2024-10-31

mitoxantrone and Leukemia

mitoxantrone has been researched along with Leukemia in 129 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)

Research Excerpts

ExcerptRelevanceReference
" Flavopiridol given by 1-hour bolus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias."9.15Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. ( Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M, 2011)
"To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia."9.10Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. ( Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL, 2002)
"The present study was undertaken to assess the feasibility, toxicity and antileukemic activity of sequential chemotherapy including mitoxantrone, etoposide, carboplatin and intermediate-dose cytarabine in adult patients with refractory and relapsed acute myelogenous (AML) or lymphoid (ALL) leukemia."9.09Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. ( Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J, 2000)
"A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent."9.08Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. ( Audhuy, B; Berthou, C; Cahn, JY; Caillot, D; Casassus, P; Colombat, P; Desablens, B; Guyotat, D; Harousseau, JL; Ifrah, N; Lamy, Y; Maloisel, F; Moreau, P; Pignon, B; Sadoun, A; Solary, E; Witz, B, 1996)
"BHAC-MMP therapy, a combination of behenoyl-ara-C, mitoxantrone, 6-mercaptopurine and prednisolone, was applied to 49 patients with acute leukemia for remission induction."9.06[A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Shibata, H; Yasunaga, K; Yonezawa, T, 1986)
"Twenty-two patients with relapsed or refractory acute leukemia received 31 treatment courses of mitoxantrone (10 to 12 mg/m2/d) as a one-hour infusion for five days."9.06A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ( Choi, KE; Daly, KM; Han, DS; Larson, RA; Sinkule, JA, 1987)
"A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine."9.05Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984)
"Despite the long-standing and extensive use of mitoxantrone (MTZ) for the treatment of aggressive forms of multiple sclerosis (MS), especially in Europe, its benefit-risk profile remains controversial."8.89Mitoxantrone-related acute leukemia in MS: an open or closed book? ( Chan, A; Lo-Coco, F, 2013)
"The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy."8.86Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. ( Gronseth, G; Marriott, JJ; Miyasaki, JM; O'Connor, PW, 2010)
"Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate."8.83The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006)
"Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events."8.82Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004)
"To evaluate the incidence of therapy-related acute leukaemia (t-AL) after single-agent mitoxantrone (MITO) treatment, we reviewed medical records of patients in three studies of single-agent MITO therapy for multiple sclerosis (MS) and existing literature on MITO therapy in MS, leukaemia, and solid tumors."8.81A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. ( Butine, MD; De Goodkin, DE; Edan, G; Eisenmann, S; Ghalie, RG; Gonsette, RE; Hartung, HP; Le Page, E; Mauch, E, 2002)
"5 years suggests that the risk of either therapy-related acute leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis is low when patients are treated within standard protocol."7.78Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012)
"Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported."7.78Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012)
"Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS)."7.76[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. ( Ansorge, N; Chan, A; Dührsen, U; Gold, R; Meyer, C; Nückel, H; Ritter, PR; Salmen, S; Schmidt, WE; Siglienti, I; Stroet, A, 2010)
"Mitoxantrone (Mx) is used as a second-line treatment in multiple sclerosis."7.73[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]. ( Baldauf, E; Berger, E; Deconinck, E; Nollet, S; Rumbach, L, 2006)
"The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)."7.69Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994)
"Fourteen patients with relapsed or refractory acute leukemia received combination chemotherapy of mitoxantrone 6 mg/m2/day intravenously for three to six days and cytosine arabinoside 60 mg/m2/day intravenously over 24 hours continuously for five to ten days."7.68[Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia]. ( Fujiwara, Y; Murase, T; Ohkita, T; Tanaka, M; Uchida, T; Wakita, A, 1992)
"Fifteen adult patients with relapsed or refractory acute leukemia were treated with quinine formiate (30 mg/kg/d in continuous intravenous (IV) infusion from day 1 through day 5 or 6) associated with Ara-C (1 g/m2 in 3-hour IV infusion twice a day for 5 days) and five increasing doses of mitoxantrone (from 8 mg/m2/d for 4 days to 12 mg/m2/d for 5 days)."7.68Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. ( Caillot, D; Casasnovas, RO; Chauffert, B; Dumas, M; Guy, H; Maynadie, M; Solary, E, 1992)
"Forty-six patients with acute leukemia were treated with mitoxantrone as a single agent."7.67Mitoxantrone in the treatment of acute leukemia. ( Coccia-Portugal, MA; Falkson, G; Terblanche, AP; Vorobiof, DA, 1987)
"Thirty cases of acute leukemia in patients over 15 years of age (18 males and 12 females) were treated with combinations containing mitoxantrone between January 1986 and August 1987 at the Kuwait Cancer Control Center."7.67Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. ( Baker, H; Fayyaz, S; Khalifa, F; Salfiti, R; Samir Motawy, M, 1989)
"Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy."7.67Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985)
"Mitoxantrone, a new anthracenedione, was administered to twenty-five evaluable patients with relapsed or refractory acute leukemia between January 1982 and September 1984."7.67[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Hattori, M; Kaneko, Y; Kumai, R; Maseki, N; Sakurai, M; Sampi, K, 1985)
"Twenty-four patients with acute leukemia and blast crisis of chronic myelocytic leukemia in relapse or refractory to standard chemotherapy were eligible for treatment with mitoxantrone."7.67Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Ho, AD; Meyer, P; Mjaaland, I; Ostendorf, P; Seither, E, 1985)
"We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse."7.67Phase I-II trial of mitoxantrone in acute leukemia: an interim report. ( Arlin, ZA; Bertino, J; Cassileth, P; Dukart, G; Gams, R; Moore, J; Reisman, A; Schoch, I; Silver, RA, 1985)
"Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone."7.67Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985)
"A phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione) was conducted in 35 patients (22 male: 13 female) with acute leukemia."7.67A phase II study of mitoxantrone in acute leukemia. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1985)
"Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia."7.67Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985)
"Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days."7.67Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988)
"A phase II study of mitoxantrone was conducted on acute leukemia."7.67[A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1986)
"A phase II study of acute leukemia with mitoxantrone (MIT) was conducted by the Tokai Blood Cancer Study Group."7.67[Phase II study of mitoxantrone in patients with acute leukemia]. ( Hirano, M; Ikeda, Y; Kimura, K; Kobayashi, M; Ohara, K; Ohta, K; Shirakawa, S; Yamada, K; Yoshikawa, H; Yoshikawa, S, 1986)
"A total of seventeen patients with acute leukemia were treated with mitoxantrone for induction therapy."7.67[Phase II study of mitoxantrone for acute leukemia]. ( Hirayama, F; Kanakura, Y; Kubota, Y; Masaoka, T; Nakamura, H; Oguma, S; Shibata, H; Tani, Y; Tatsumi, Y; Ueda, T, 1984)
"Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984."7.67[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986)
"A multidrug-resistant variant of the human HL-60 promyelocytic leukemia cell line (HL-60/MX2) has been isolated in vitro by subculturing these cells in progressively increasing concentrations of mitoxantrone."7.67Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. ( Dalton, WS; Harker, WG; Meltzer, PS; Slade, DL; Trent, JM, 1989)
"Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)."7.66Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983)
"Mitoxantrone was administered to 41 adults with refractory acute leukemia."7.66Phase II trial of mitoxantrone in refractory acute leukemia. ( Bodey, GP; Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB, 1983)
"Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)."6.66Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985)
"Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties."6.65Mitoxantrone in relapsed and refractory acute leukemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984)
"Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US)."5.17Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. ( Bock, D; Dangond, F; Jeffery, DR; Rivera, VM; Weinstock-Guttman, B, 2013)
" Flavopiridol given by 1-hour bolus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias."5.15Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. ( Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M, 2011)
"To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia."5.10Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. ( Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL, 2002)
"The present study was undertaken to assess the feasibility, toxicity and antileukemic activity of sequential chemotherapy including mitoxantrone, etoposide, carboplatin and intermediate-dose cytarabine in adult patients with refractory and relapsed acute myelogenous (AML) or lymphoid (ALL) leukemia."5.09Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. ( Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J, 2000)
"A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent."5.08Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. ( Audhuy, B; Berthou, C; Cahn, JY; Caillot, D; Casassus, P; Colombat, P; Desablens, B; Guyotat, D; Harousseau, JL; Ifrah, N; Lamy, Y; Maloisel, F; Moreau, P; Pignon, B; Sadoun, A; Solary, E; Witz, B, 1996)
"Sixteen adult patients with relapsed (7 patients) or refractory (9 patients) acute leukemia received mitoxantrone (10 mg/m2 per day for 3 days) and etoposide (200 mg/m2 per day for 3 days) with escalating dose of cyclosporin A (CsA) from a loading dose of 2 mg to 6."5.07Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). ( Bastie, JN; Baumelou, E; Casassus, P; Coloma, F; Delmas-Marsalet, B; Delmer, A; Faussat Suberville, AM; Leroux, G; Marie, JP; Rio, B, 1993)
"Twenty-two patients with relapsed or refractory acute leukemia received 31 treatment courses of mitoxantrone (10 to 12 mg/m2/d) as a one-hour infusion for five days."5.06A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ( Choi, KE; Daly, KM; Han, DS; Larson, RA; Sinkule, JA, 1987)
"BHAC-MMP therapy, a combination of behenoyl-ara-C, mitoxantrone, 6-mercaptopurine and prednisolone, was applied to 49 patients with acute leukemia for remission induction."5.06[A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Shibata, H; Yasunaga, K; Yonezawa, T, 1986)
"A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine."5.05Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984)
"Therapy-related acute leukaemia (TRAL) is a significant concern, when considering treatment with mitoxantrone for multiple sclerosis (MS)."4.91Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? ( Boggild, M; Brown, S; Ellis, R, 2015)
"Despite the long-standing and extensive use of mitoxantrone (MTZ) for the treatment of aggressive forms of multiple sclerosis (MS), especially in Europe, its benefit-risk profile remains controversial."4.89Mitoxantrone-related acute leukemia in MS: an open or closed book? ( Chan, A; Lo-Coco, F, 2013)
"The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy."4.86Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. ( Gronseth, G; Marriott, JJ; Miyasaki, JM; O'Connor, PW, 2010)
"Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate."4.83The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006)
"Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events."4.82Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004)
"To evaluate the incidence of therapy-related acute leukaemia (t-AL) after single-agent mitoxantrone (MITO) treatment, we reviewed medical records of patients in three studies of single-agent MITO therapy for multiple sclerosis (MS) and existing literature on MITO therapy in MS, leukaemia, and solid tumors."4.81A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. ( Butine, MD; De Goodkin, DE; Edan, G; Eisenmann, S; Ghalie, RG; Gonsette, RE; Hartung, HP; Le Page, E; Mauch, E, 2002)
"New clinical strategies and innovative approaches to the use of mitoxantrone include high-dose treatment, new combinations such as 5-fluorouracil with leucovorin (NFL), and neoadjuvant therapy for metastatic and primary breast cancer."4.79Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction. ( Powles, TJ, 1997)
"Mitoxantrone, a cytotoxic anthracenedione derivative, has given clinical evidence of beneficial activity in breast cancer, lymphoma and leukaemia."4.78Pharmacokinetics and metabolism of mitoxantrone. A review. ( Blanz, J; Ehninger, G; Proksch, B; Schuler, U; Zeller, KP, 1990)
"Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported."3.78Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012)
"5 years suggests that the risk of either therapy-related acute leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis is low when patients are treated within standard protocol."3.78Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012)
"Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS)."3.76[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. ( Ansorge, N; Chan, A; Dührsen, U; Gold, R; Meyer, C; Nückel, H; Ritter, PR; Salmen, S; Schmidt, WE; Siglienti, I; Stroet, A, 2010)
"In breast cancer, mitoxantrone's response rate as a single agent is 25-30%, while combination regimens produce response rates of 60% or more."3.76Mitoxantrone: a novel anthracycline derivative. ( Eble, M; Koeller, J, 1988)
"Mitoxantrone (Mx) is used as a second-line treatment in multiple sclerosis."3.73[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]. ( Baldauf, E; Berger, E; Deconinck, E; Nollet, S; Rumbach, L, 2006)
"The combination of adjuvant radiotherapy and chemotherapy with mitoxantrone induces a high risk of acute leukemia in patients with breast cancer."3.70Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. ( Bonithon-Kopp, C; Carli, PM; Chaplain, G; Milan, C; Sgro, C, 2000)
"Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF."3.70Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L, 1999)
"The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)."3.69Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994)
"Fifteen adult patients with relapsed or refractory acute leukemia were treated with quinine formiate (30 mg/kg/d in continuous intravenous (IV) infusion from day 1 through day 5 or 6) associated with Ara-C (1 g/m2 in 3-hour IV infusion twice a day for 5 days) and five increasing doses of mitoxantrone (from 8 mg/m2/d for 4 days to 12 mg/m2/d for 5 days)."3.68Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. ( Caillot, D; Casasnovas, RO; Chauffert, B; Dumas, M; Guy, H; Maynadie, M; Solary, E, 1992)
"Fourteen patients with relapsed or refractory acute leukemia received combination chemotherapy of mitoxantrone 6 mg/m2/day intravenously for three to six days and cytosine arabinoside 60 mg/m2/day intravenously over 24 hours continuously for five to ten days."3.68[Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia]. ( Fujiwara, Y; Murase, T; Ohkita, T; Tanaka, M; Uchida, T; Wakita, A, 1992)
"Forty-six patients with acute leukemia were treated with mitoxantrone as a single agent."3.67Mitoxantrone in the treatment of acute leukemia. ( Coccia-Portugal, MA; Falkson, G; Terblanche, AP; Vorobiof, DA, 1987)
"A phase II study of acute leukemia with mitoxantrone (MIT) was conducted by the Tokai Blood Cancer Study Group."3.67[Phase II study of mitoxantrone in patients with acute leukemia]. ( Hirano, M; Ikeda, Y; Kimura, K; Kobayashi, M; Ohara, K; Ohta, K; Shirakawa, S; Yamada, K; Yoshikawa, H; Yoshikawa, S, 1986)
"A total of seventeen patients with acute leukemia were treated with mitoxantrone for induction therapy."3.67[Phase II study of mitoxantrone for acute leukemia]. ( Hirayama, F; Kanakura, Y; Kubota, Y; Masaoka, T; Nakamura, H; Oguma, S; Shibata, H; Tani, Y; Tatsumi, Y; Ueda, T, 1984)
"A phase II study of mitoxantrone was conducted on acute leukemia."3.67[A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1986)
"The plasma kinetics of mitoxantrone (MX), a new cytostatic anthracenedione, were investigated with HPLC in five leukemic patients suffering from acute myeloid leukemia, at the dose of 24 mg m-2 infused over 30 min at constant rate."3.67Plasma kinetics of mitoxantrone in leukemic patients. ( Dumont, E; Harvengt, C; Hulhoven, R, 1984)
"Among new drugs being studied currently, AMSA and mitoxantrone have shown significant usefulness against acute non-lymphocytic leukemia in adults."3.67[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults]. ( Ogawa, M, 1986)
"Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia."3.67Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985)
"A multidrug-resistant variant of the human HL-60 promyelocytic leukemia cell line (HL-60/MX2) has been isolated in vitro by subculturing these cells in progressively increasing concentrations of mitoxantrone."3.67Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. ( Dalton, WS; Harker, WG; Meltzer, PS; Slade, DL; Trent, JM, 1989)
"Mitoxantrone was administered as a single iv injection once every 3 weeks to 84 children with advanced acute leukemia and solid tumors in a phase I trial."3.67Phase I trial of mitoxantrone in children. ( Cohen, LF; Glaubiger, DL; Holcenberg, JS; Kamen, BA; Pratt, CB; Ungerleider, RS; Vietti, TJ, 1985)
"A phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione) was conducted in 35 patients (22 male: 13 female) with acute leukemia."3.67A phase II study of mitoxantrone in acute leukemia. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1985)
"Thirty cases of acute leukemia in patients over 15 years of age (18 males and 12 females) were treated with combinations containing mitoxantrone between January 1986 and August 1987 at the Kuwait Cancer Control Center."3.67Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. ( Baker, H; Fayyaz, S; Khalifa, F; Salfiti, R; Samir Motawy, M, 1989)
"Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days."3.67Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988)
"We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse."3.67Phase I-II trial of mitoxantrone in acute leukemia: an interim report. ( Arlin, ZA; Bertino, J; Cassileth, P; Dukart, G; Gams, R; Moore, J; Reisman, A; Schoch, I; Silver, RA, 1985)
"Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone."3.67Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985)
"Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984."3.67[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986)
"Twenty-four patients with acute leukemia and blast crisis of chronic myelocytic leukemia in relapse or refractory to standard chemotherapy were eligible for treatment with mitoxantrone."3.67Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Ho, AD; Meyer, P; Mjaaland, I; Ostendorf, P; Seither, E, 1985)
"Mitoxantrone, a new anthracenedione, was administered to twenty-five evaluable patients with relapsed or refractory acute leukemia between January 1982 and September 1984."3.67[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Hattori, M; Kaneko, Y; Kumai, R; Maseki, N; Sakurai, M; Sampi, K, 1985)
"Eleven patients with acute leukemia were treated with MB-triple V therapy consisting of mitoxantrone, behenoyl-arabinoside, etoposide, vincristine and vindesine."3.67[Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy]. ( Furukawa, Y; Im, T; Inoue, T; Kishida, T; Park, K; Sasaki, A; Tatsumi, N; Yamane, T, 1989)
"Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy."3.67Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985)
"Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)."3.66Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983)
"Mitoxantrone was administered to 41 adults with refractory acute leukemia."3.66Phase II trial of mitoxantrone in refractory acute leukemia. ( Bodey, GP; Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB, 1983)
"Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)."2.66Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985)
"Mitoxantrone is an active and relatively non-toxic agent which merits further assessment prior to its incorporation in first-line therapy of acute leukaemia."2.65Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1983)
"Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties."2.65Mitoxantrone in relapsed and refractory acute leukemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984)
" The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents."1.35The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. ( Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)
"The most frequent cancers were breast (34."1.35Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008)
"Verapamil did not increase DNR toxicity in four of these eight cases, but was more efficient in one other MDR1(+) case."1.30Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. ( Faussat, AM; Marie, JP; Simonin, G; Zhou, DC; Zittoun, R, 1997)
"Mitoxantrone was extracted directly from plasma samples with a plastic mini-column packed with non-bonded silica gel and eluted with the above elution solvent."1.28High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation. ( Leclerc, JM; Lin, KT; Rivard, GE, 1989)

Research

Studies (129)

TimeframeStudies, this research(%)All Research%
pre-199059 (45.74)18.7374
1990's28 (21.71)18.2507
2000's24 (18.60)29.6817
2010's15 (11.63)24.3611
2020's3 (2.33)2.80

Authors

AuthorsStudies
Mei, SX1
Jiang, B1
Niu, XM1
Li, ML1
Yang, H1
Na, Z1
Lin, ZW1
Li, CM1
Sun, HD1
Das, SG1
Doshi, JM1
Tian, D1
Addo, SN1
Srinivasan, B1
Hermanson, DL1
Xing, C1
Nguyen, HT1
Song, GY1
Kim, JA1
Hyun, JH1
Kang, HK1
Kim, YH1
Li, B1
Hu, M1
Chen, C1
Yin, H1
Deng, Y1
Li, H1
Zhang, J1
He, L1
Kim, H1
Jung, I1
Lee, CH1
An, J1
Ko, M1
Jing, W1
Zhou, M1
Chen, R1
Ye, X1
Li, W1
Su, X1
Luo, J1
Wang, Z1
Peng, S1
Chan, A2
Lo-Coco, F1
Shi, Y1
Su, Z1
Li, S1
Chen, Y1
Chen, X1
Xiao, Y1
Sun, M1
Ping, Q1
Zong, L1
Rivera, VM1
Jeffery, DR1
Weinstock-Guttman, B1
Bock, D1
Dangond, F1
Kostrzewa-Nowak, D1
Tarasiuk, J1
Ellis, R1
Brown, S1
Boggild, M1
Deeren, D1
Tanaka, M2
Kano, Y2
Akutsu, M2
Tsunoda, S2
Izumi, T2
Yazawa, Y1
Miyawaki, S1
Mano, H2
Furukawa, Y3
Marriott, JJ1
Miyasaki, JM1
Gronseth, G1
O'Connor, PW1
Gopinath, SC1
Wadhwa, R1
Kumar, PK1
Meyer, C1
Ansorge, N1
Siglienti, I1
Salmen, S1
Stroet, A1
Nückel, H1
Dührsen, U1
Ritter, PR1
Schmidt, WE1
Gold, R1
Karp, JE1
Smith, BD1
Resar, LS1
Greer, JM1
Blackford, A1
Zhao, M1
Moton-Nelson, D1
Alino, K1
Levis, MJ1
Gore, SD1
Joseph, B1
Carraway, H1
McDevitt, MA1
Bagain, L1
Mackey, K1
Briel, J1
Doyle, LA1
Wright, JJ1
Rudek, MA1
Le Page, E2
Leray, E1
Edan, G2
Gupta, A1
Le, A1
Belinka, BA1
Kachlany, SC1
Mulroy, E1
Joyce, E1
Scott, J1
Melling, J1
Goggin, C1
Mahon, N1
O'Rourke, K1
Lynch, T1
Colovic, N1
Suvajdzic, N1
Kraguljac Kurtovic, N1
Djordjevic, V1
Dencic Fekete, M1
Drulovic, J1
Vidovic, A1
Tomin, D1
Cowell, IG1
Austin, CA1
Mainwaring, MG1
Rimsza, LM1
Chen, SF1
Gomez, SP1
Weeks, FW1
Reddy, V1
Lynch, J1
May, WS1
Kahn, S1
Moreb, J1
Leather, H1
Braylan, R1
Rowe, TC1
Fieniewicz, KJ1
Wingard, JR1
Ghalie, RG1
Mauch, E1
Hartung, HP1
Gonsette, RE1
Eisenmann, S1
Butine, MD1
De Goodkin, DE1
Cohen, BA1
Mikol, DD1
Seiter, K2
Güven, GS1
Ozçakar, L1
Koçak, T1
Aksu, S1
Kogoshi, H1
Tohda, S1
Fu, L1
Koyama, T1
Nara, N1
Kansu, E1
Koc, Y1
Kars, A1
Alakavuklar, M1
Tekuzman, G1
Firat, D1
Murray, TJ1
Nollet, S1
Berger, E1
Deconinck, E1
Baldauf, E1
Rumbach, L2
Vu, HA1
Odgerel, T1
Matsuo, Y1
Kirito, K1
Sato, Y1
Huang, XJ1
Liu, DH1
Liu, KY1
Xu, LP1
Chen, H1
Han, W1
Böttger, S1
Jerszyk, E1
Low, B1
Walker, C1
Lebrun, C1
Debouverie, M1
Vermersch, P1
Clavelou, P1
de Seze, J1
Wiertlevski, S1
Defer, G1
Gout, O1
Berthier, F1
Danzon, A1
Gahrton, G1
Smith, IE1
Cheng, CC1
Zee-Cheng, RK1
Prentice, HG5
Robbins, G3
Ma, DD3
Ho, AD5
Paciucci, PA2
Cuttner, J2
Holland, JF2
Moore, JO2
Olsen, GA1
Nathanson, L1
Hulhoven, R1
Dumont, E1
Harvengt, C1
Masaoka, T6
Ueoka, H1
Ueno, K1
Yamane, T2
Toyoda, K1
Endo, H1
Nishihara, R1
Takahashi, I1
Ohnoshi, T2
Kitajima, K1
Kimura, I2
Oguma, S3
Tatsumi, Y1
Hirayama, F1
Tani, Y1
Kubota, Y1
Kanakura, Y1
Ueda, T1
Nakamura, H1
Shibata, H4
Dalton, WS2
Alberts, DS1
Estey, EH2
Keating, MJ2
McCredie, KB1
Bodey, GP1
Freireich, EJ1
Ohnuma, T1
Silver, RT1
Macdonald, JS1
Marsoni, S1
Bruno, S1
Poster, D1
Meckenstock, G1
Heyll, A1
Schneider, EM1
Hildebrandt, B1
Runde, V1
Aul, C1
Bartram, CR1
Ludwig, WD1
Schneider, W1
Wells, RJ1
Odom, LF1
Gold, SH1
Feusner, J1
Krill, CE1
Waldron, P1
Moulton, TA1
Knoppell, E1
White, ML1
Cairo, MS1
Solary, E4
Witz, F1
Moreau, P2
Quiquandon, I1
Genne, P1
Flesch, M1
Saddoun, A1
Maloisel, F3
Pignon, B2
Abgrall, JF1
Marie, JP2
Bastie, JN1
Coloma, F1
Faussat Suberville, AM1
Delmer, A1
Rio, B1
Delmas-Marsalet, B1
Leroux, G1
Casassus, P3
Baumelou, E1
Lyytikäinen, O1
Elonen, E1
Lautenschlager, I1
Jokipii, A1
Tiittanen, L1
Ruutu, P1
Gandhi, V1
Plunkett, W2
Witz, B1
Caillot, D2
Desablens, B1
Cahn, JY1
Sadoun, A1
Berthou, C1
Guyotat, D1
Ifrah, N1
Lamy, Y1
Audhuy, B1
Colombat, P1
Harousseau, JL1
Doi, T1
Sakamaki, S1
Koike, K1
Matsunaga, T1
Kobayashi, D1
Muramatsu, H1
Sato, T1
Watanabe, N1
Kougo, Y1
Niitsu, Y1
Vial, JP1
Belloc, F1
Dumain, P1
Besnard, S1
Lacombe, F1
Boisseau, MR1
Reiffers, J2
Bernard, P1
Brodsky, AL1
Melero, MJ1
Minissale, CJ1
Sánchez Avalos, JC1
Asschert, J1
de Vries, E1
van der Kolk, D1
Müller, M1
Vellenga, E1
Zhou, DC1
Simonin, G1
Faussat, AM1
Zittoun, R1
Powles, TJ1
Killick, S1
Matutes, E1
Swansbury, J1
Catovsky, D1
Wattel, E1
Leleu, X1
Dreyfus, F1
Brion, A1
Jouet, JP1
Hoang-Ngoc, L1
Guerci, A1
Rochant, H1
Gratecos, N1
Janvier, M1
Brice, P1
Lepelley, P1
Fenaux, P1
Alessandrino, EP1
Bernasconi, P1
Caldera, D1
Colombo, A1
Malcovati, L1
Martinelli, G1
Bonfichi, M1
Pagnucco, G1
Salvaneschi, L1
Bernasconi, C2
Macnamara, B1
Palucka, KA1
Porwit-MacDonald, A1
Salvucci, M1
Zanchini, R1
Molinari, A1
Zuffa, E1
Poletti, V1
Poletti, G1
Zaccaria, A1
Chaplain, G1
Milan, C1
Sgro, C1
Carli, PM1
Bonithon-Kopp, C1
Bajwa, RP1
Skinner, R1
Windebank, KP1
Wariyar, UK1
Reid, MM1
Nair, JS1
Kancherla, R1
Traganos, F1
Tse-Dinh, YC1
Ferrá, C1
Berlanga, JJ1
Gallardo, D1
Ancín, I1
Marín, D1
González, JR1
Peris, J1
Muñoz, J1
Sarrá, J1
Grañena, A1
Kern, W1
Schleyer, E1
Braess, J1
Wittmer, E1
Ohnesorge, J1
Unterhalt, M1
Wörmann, B1
Büchner, T2
Hiddemann, W2
Budman, DR1
Calabro, A1
Kreis, W1
Rizzieri, DA1
Bass, AJ1
Rosner, GL1
Gockerman, JP1
DeCastro, CM1
Petros, WP1
Adams, DJ1
Laughlin, MJ1
Davis, P1
Foster, T1
Jacobson, R1
Hurwitz, H1
Takahashi, A1
Yamamoto, K1
Okuma, M1
Sasada, M1
Chauffert, B1
Casasnovas, RO1
Dumas, M1
Maynadie, M1
Guy, H1
Wakita, A1
Murase, T1
Uchida, T1
Fujiwara, Y1
Ohkita, T1
Birchall, LA1
Bailey, NP1
Blackledge, GR1
Heinemann, V1
Estey, E1
Keating, M1
Ehninger, G3
Schuler, U1
Proksch, B1
Zeller, KP1
Blanz, J1
Kumar, L1
Kochipillai, V1
Coccia-Portugal, MA2
Falkson, G2
Uys, A1
Kusnierz-Glaz, C1
Reiser, M1
Hagemeister, B1
van de Loo, J1
Marit, G1
Cony, P1
Duclos, F1
Puntous, M1
Broustet, A1
Cunningham, M1
Ohtsu, T2
Ishida, Y2
Tobinai, K2
Minato, K2
Hamada, H2
Ohkochi, E1
Tsuruo, T2
Shimoyama, M2
Lin, KT1
Rivard, GE1
Leclerc, JM1
Harker, WG1
Slade, DL1
Meltzer, PS1
Trent, JM1
Sugimoto, Y1
Inoue, T1
Sasaki, A1
Kishida, T1
Park, K1
Im, T1
Tatsumi, N1
Coiffier, B1
Samir Motawy, M1
Salfiti, R1
Khalifa, F1
Fayyaz, S1
Baker, H1
Young, CW1
Raymond, V1
Koeller, J1
Eble, M1
Cotter, FE1
Takeyama, H1
Fukutani, H1
Takeo, T1
Yamada, H1
Watanabe, E1
Tsukagoshi, S1
Petti, MC1
Avvisati, G1
Tafuri, A1
Meloni, G1
Amadori, S1
Mandelli, F1
Vredenburgh, JJ1
McIntyre, OR1
Cornwell, GG1
Ball, ED1
Cornell, CJ1
Mills, LE1
O'Donnell, JF1
Okuma, K1
Ariyoshi, Y1
Ota, K1
Sampi, K2
Ogawa, M2
Yamada, K3
Wakui, A1
Meguro, S1
Nagai, K4
Kitani, T4
Seither, E3
Vorobiof, DA1
Terblanche, AP1
Shenkenberg, TD1
Von Hoff, DD1
Kanamaru, A1
Horiuchi, A3
Yonezawa, T3
Kawagoe, H3
Yasunaga, K3
Kimura, K2
Yoshikawa, H2
Yoshikawa, S2
Hirano, M2
Ikeda, Y2
Ohta, K2
Ohno, R1
Ohara, K2
Kobayashi, M2
Larson, RA2
Daly, KM2
Choi, KE2
Han, DS2
Sinkule, JA2
Sanz, MA1
Martínez, J1
Borrego, D1
Martín-Aragonés, G1
Lorenzo, I1
Sanz, G1
Sayas, MJ1
Jarque, I1
Pastor, E1
Rafecas, J1
McGrath, SC1
Spitzer, T1
Gerson, S1
Lazarus, H1
Shirakawa, S1
Arlin, ZA2
Silver, R1
Cassileth, P2
Armentrout, S1
Gams, R2
Daghestani, A1
Coleman, M1
Schoch, I3
Dukart, G3
Ungerleider, RS1
Pratt, CB1
Vietti, TJ1
Holcenberg, JS1
Kamen, BA1
Glaubiger, DL1
Cohen, LF1
Meyer, P2
Mjaaland, I2
Heidemann, E1
Reisman, A1
Moore, J1
Silver, RA1
Bertino, J1
Wimperis, JZ1
Ostendorf, P1
Klein, HO1
Kaneko, Y1
Maseki, N1
Kumai, R1
Sakurai, M1
Hattori, M1
Starling, KA1
Mulne, AF1
Vats, TS1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leu[NCT00470197]Phase 135 participants (Actual)Interventional2007-04-30Completed
Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522]Phase 223 participants (Actual)Interventional2009-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

21 reviews available for mitoxantrone and Leukemia

ArticleYear
Mitoxantrone-related acute leukemia in MS: an open or closed book?
    Neurology, 2013, Apr-16, Volume: 80, Issue:16

    Topics: Antineoplastic Agents, Alkylating; Humans; Leukemia; Mitoxantrone; Monitoring, Physiologic; Multiple

2013
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
    Multiple sclerosis (Houndmills, Basingstoke, England), 2015, Volume: 21, Issue:5

    Topics: Antineoplastic Agents; Humans; Leukemia; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relap

2015
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology, 2010, May-04, Volume: 74, Issue:18

    Topics: Adult; Cardiotoxins; Controlled Clinical Trials as Topic; Databases, Factual; Female; Humans; Leukem

2010
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2002, Volume: 8, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials, Phase III as Topic; Female; France; Germany

2002
Mitoxantrone treatment of multiple sclerosis: safety considerations.
    Neurology, 2004, Dec-28, Volume: 63, Issue:12 Suppl 6

    Topics: Animals; Cardiomyopathies; Drug Monitoring; Heart Failure; Humans; Immunosuppressive Agents; Leukemi

2004
Toxicity of the topoisomerase II inhibitors.
    Expert opinion on drug safety, 2005, Volume: 4, Issue:2

    Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirub

2005
The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
    Expert opinion on drug safety, 2006, Volume: 5, Issue:2

    Topics: Disease Progression; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia; Mitoxantrone

2006
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
    Advances in cancer research, 1983, Volume: 40

    Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinone

1983
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
    Cancer treatment reviews, 1983, Volume: 10, Issue:2

    Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi

1983
The design, synthesis and development of a new class of potent antineoplastic anthraquinones.
    Progress in medicinal chemistry, 1983, Volume: 20

    Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Clini

1983
Intracellular pharmacodynamics in leukemia therapy.
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; H

1996
Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction.
    European journal of cancer care, 1997, Volume: 6, Issue:4 Suppl

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Leukemia; Lymphoma; Mitoxantrone

1997
An overview of mitozantrone.
    The British journal of clinical practice, 1991,Autumn, Volume: 45, Issue:3

    Topics: Acute Disease; Breast Neoplasms; Female; Humans; Leukemia; Mitoxantrone; Neoplasms

1991
Pharmacologically directed design of leukemia therapy.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleo

1990
Pharmacokinetics and metabolism of mitoxantrone. A review.
    Clinical pharmacokinetics, 1990, Volume: 18, Issue:5

    Topics: Animals; Breast Neoplasms; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Leu

1990
Nonhematologic toxicities of selected chemotherapeutic agents used in the treatment of adult leukemia.
    Seminars in oncology nursing, 1990, Volume: 6, Issue:1

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans;

1990
Etoposide: fifteen years experience.
    Bone marrow transplantation, 1989, Volume: 4 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Dise

1989
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Cancer treatment reports, 1986, Volume: 70, Issue:1

    Topics: Aclarubicin; Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Cell Survival

1986
Mitoxantrone: a novel anthracycline derivative.
    Clinical pharmacy, 1988, Volume: 7, Issue:8

    Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi

1988
Therapeutic milestones. Novantrone (mitozantrone).
    The British journal of clinical practice, 1988, Volume: 42, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leukemia; Lymphoma

1988
Mitoxantrone: a new anticancer drug with significant clinical activity.
    Annals of internal medicine, 1986, Volume: 105, Issue:1

    Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T

1986

Trials

26 trials available for mitoxantrone and Leukemia

ArticleYear
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
    BMC neurology, 2013, Jul-11, Volume: 13

    Topics: Adult; Aged; Female; Heart Failure; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Scle

2013
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
    Blood, 2011, Mar-24, Volume: 117, Issue:12

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2011
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragment

2002
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
    Haematologica, 2007, Volume: 92, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine;

2007
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
    Cancer treatment reviews, 1983, Volume: 10, Issue:2

    Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi

1983
The design, synthesis and development of a new class of potent antineoplastic anthraquinones.
    Progress in medicinal chemistry, 1983, Volume: 20

    Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Clini

1983
Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia.
    Cancer treatment reviews, 1983, Volume: 10 Suppl B

    Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Cells, Cultured; Clinical Trials

1983
Mitoxantrone in relapsed and refractory acute leukemia.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Acute Disease; Aged; Anthraquinones; Antineoplastic Agents; Cell Line; Clinical Trials as Topic; Fol

1984
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combin

1984
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Seminars in oncology, 1984, Volume: 11, Issue:3 Suppl 1

    Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Clinical Trials as Topic; Drug Ad

1984
Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL).
    Leukemia, 1993, Volume: 7, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

1993
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
    Blood, 1996, Aug-15, Volume: 88, Issue:4

    Topics: Acute Disease; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells

1996
[Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
    Medicina, 1996, Volume: 56, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anti

1996
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
    Leukemia, 1999, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation

1999
Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
    Leukemia & lymphoma, 2000, Volume: 39, Issue:5-6

    Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols

2000
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
    Annals of hematology, 2001, Volume: 80, Issue:6

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free

2001
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-01, Volume: 20, Issue:3

    Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2002
[Evaluation of mitoxantrone in 1989].
    Pathologie-biologie, 1989, Volume: 37, Issue:9

    Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Leukemia; Lymphoma; Mal

1989
Mitoxantrone: a novel anthracycline derivative.
    Clinical pharmacy, 1988, Volume: 7, Issue:8

    Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi

1988
The role of mitozantrone in the treatment of acute leukaemia.
    Acta haematologica, 1987, Volume: 78 Suppl 1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical

1987
[Introduction of a new anticancer drug, novantrone].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:11

    Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical;

1987
Mitoxantrone: a new anticancer drug with significant clinical activity.
    Annals of internal medicine, 1986, Volume: 105, Issue:1

    Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T

1986
[A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protoco

1986
[Mitoxantrone as combination chemotherapy in patients with acute leukemia. Tokai Blood Cancer Study Group].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1986, Volume: 27, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Clini

1986
A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:3

    Topics: Acute Disease; Adult; Aged; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Female;

1987
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone

1985

Other Studies

86 other studies available for mitoxantrone and Leukemia

ArticleYear
Abietane diterpenoids from Coleus xanthanthus.
    Journal of natural products, 2002, Volume: 65, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Diterpenes; Drug Screening Assays, Antitumor; Drugs, Chinese Herb

2002
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
    Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

    Topics: Apoptosis; Benzopyrans; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia;

2009
Dammarane-type saponins from the flower buds of Panax ginseng and their effects on human leukemia cells.
    Bioorganic & medicinal chemistry letters, 2010, Jan-01, Volume: 20, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Dammaranes; Flowers; HL-60 Cells; Humans; Leukemia; Magnetic Reso

2010
Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives.
    Bioorganic & medicinal chemistry letters, 2022, 10-01, Volume: 73

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Screening As

2022
Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins.
    International journal of molecular sciences, 2023, Nov-15, Volume: 24, Issue:22

    Topics: 5-Methylcytosine; Animals; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic;

2023
In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
    Oncology reports, 2021, Volume: 45, Issue:3

    Topics: Adenosine Triphosphatases; Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily

2021
Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease.
    Molecular pharmaceutics, 2013, Jun-03, Volume: 10, Issue:6

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Drug Delivery Systems; Durapatite; Fo

2013
Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
    European journal of pharmacology, 2013, Dec-05, Volume: 721, Issue:1-3

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Multiple; HL-60 C

2013
Treatment of invasive aspergillosis with nonmyeloablative allogeneic stem cell transplantation: the hunter becomes the hunted.
    American journal of hematology, 2008, Volume: 83, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Cytarabine; Female; Hematopoie

2008
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Anticancer research, 2009, Volume: 29, Issue:11

    Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens,

2009
Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance.
    Molecular cancer research : MCR, 2010, Volume: 8, Issue:11

    Topics: Antineoplastic Agents; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; G

2010
[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].
    Der Nervenarzt, 2010, Volume: 81, Issue:12

    Topics: Adult; Analgesics; Humans; Leukemia; Male; Mitoxantrone; Multiple Sclerosis; Thrombocytopenia

2010
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2011, Volume: 17, Issue:7

    Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl

2011
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
    Leukemia research, 2011, Volume: 35, Issue:11

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busul

2011
Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
    European neurology, 2012, Volume: 67, Issue:1

    Topics: Adult; Aged; Cardiomyopathies; Female; Follow-Up Studies; Humans; Leukemia; Male; Middle Aged; Mitox

2012
Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:3

    Topics: Acute Disease; Adult; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis,

2012
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
    Cell cycle (Georgetown, Tex.), 2012, Sep-01, Volume: 11, Issue:17

    Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epir

2012
Knee arthritis as a rare inaugural manifestation of adult leukemia.
    Rheumatology international, 2005, Volume: 25, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cytarabine; Diagnosis, Differentia

2005
Effect of notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells.
    Oncology reports, 2005, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Calcium-Binding Proteins; Caspase 3; Caspases; Cell Line, Tumor; Cell Prolife

2005
Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as T

1989
[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].
    Revue neurologique, 2006, Volume: 162, Issue:2

    Topics: Acute Disease; Adult; Analgesics; Blood Cell Count; Female; Humans; Leukemia; Middle Aged; Mitoxantr

2006
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
    Leukemia, 2007, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubici

2007
Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.
    Cancer research, 2008, Feb-01, Volume: 68, Issue:3

    Topics: Amino Acid Sequence; Animals; Apoptosis; DNA Damage; Etoposide; Fatty Acids, Unsaturated; Hemocytes;

2008
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
    Multiple sclerosis (Houndmills, Basingstoke, England), 2008, Volume: 14, Issue:3

    Topics: Adult; Azathioprine; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Digestive

2008
Mitoxantrone.
    Cancer treatment reviews, 1984, Volume: 11, Issue:4

    Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Evaluation; Hear

1984
Plasma kinetics of mitoxantrone in leukemic patients.
    Medical oncology and tumor pharmacotherapy, 1984, Volume: 1, Issue:3

    Topics: Anthraquinones; Antineoplastic Agents; Humans; Kinetics; Leukemia; Mitoxantrone

1984
[Treatment of acute leukemia in relapse].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:11

    Topics: Acute Disease; Adult; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; H

1983
[Phase II study of mitoxantrone for hematologic malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Hu

1983
[Phase II study of mitoxantrone for acute leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Drug Administration Schedule; Drug Evaluation; Fem

1984
Mitoxantrone: a promising new chemotherapeutic agent.
    Arizona medicine, 1984, Volume: 41, Issue:2

    Topics: Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Humans; Leukemia; Mitoxant

1984
Phase II trial of mitoxantrone in refractory acute leukemia.
    Cancer treatment reports, 1983, Volume: 67, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration S

1983
Mitoxantrone in patients with acute leukemia in relapse.
    Cancer research, 1983, Volume: 43, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Child; Drug Administration

1983
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1982, Volume: 80

    Topics: Adenosine Deaminase Inhibitors; Aminoacridines; Amsacrine; Anthracenes; Antineoplastic Agents; Cofor

1982
Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
    Leukemia, 1995, Volume: 9, Issue:2

    Topics: Acute Disease; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio

1995
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1.
    Medical and pediatric oncology, 1994, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter,

1994
[Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia].
    Nouvelle revue francaise d'hematologie, 1994, Volume: 36 Suppl 2

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia;

1994
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
    European journal of haematology, 1996, Volume: 56, Issue:3

    Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmus

1996
[CD7, HLA-DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1996, Volume: 37, Issue:8

    Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD7; Antigens, Di

1996
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells.
    Leukemia research, 1997, Volume: 21, Issue:2

    Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents;

1997
The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
    Leukemia, 1997, Volume: 11, Issue:5

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cyclosporins; Daunorubicin;

1997
Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells.
    Leukemia, 1997, Volume: 11, Issue:9

    Topics: Acridines; Acute Disease; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane Per

1997
Case 17: Essential thrombocythaemia with inversion 3 terminating in acute leukaemia.
    Leukemia & lymphoma, 1998, Volume: 30, Issue:5-6

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Hu

1998
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
    Bone marrow transplantation, 1999, Volume: 23, Issue:6

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined

1999
Balance between proliferation and apoptosis in leukemic cell lines resistant to cytostatics.
    Leukemia & lymphoma, 1999, Volume: 36, Issue:1-2

    Topics: Antineoplastic Agents; Apoptosis; Cell Division; Dose-Response Relationship, Drug; Drug Resistance,

1999
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
    Haematologica, 2000, Volume: 85, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; I

2000
Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Coh

2000
Chemotherapy and marrow transplantation for congenital leukaemia.
    Archives of disease in childhood. Fetal and neonatal edition, 2001, Volume: 84, Issue:1

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplanta

2001
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials,

2000
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
    Leukemia, 2001, Volume: 15, Issue:10

    Topics: Acute Disease; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cytarabin

2001
Bone marrow stromal cells attenuate mitoxantrone cytotoxicity against HL-60 leukemic cells.
    Anti-cancer drugs, 1992, Volume: 3, Issue:6

    Topics: Cell Adhesion; Cell Survival; Fibroblasts; Hematopoietic Stem Cells; Humans; Leukemia; Mitoxantrone;

1992
Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding

1992
[Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:5

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cy

1992
Mitoxantrone induced hyperpigmentation.
    The New Zealand medical journal, 1990, Feb-14, Volume: 103, Issue:883

    Topics: Acute Disease; Adult; Facial Dermatoses; Hand Dermatoses; Humans; Leukemia; Male; Mitoxantrone; Nail

1990
Mitoxantrone in the treatment of acute leukemia.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Evaluation; Female; Humans; Le

1990
Magnetic resonance imaging follow-up in patients with acute leukemia during induction chemotherapy.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols;

1990
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl

1990
A novel multidrug resistance in cultured leukemia and lymphoma cells detected by a monoclonal antibody to 85-kDa protein, MRK20.
    Japanese journal of cancer research : Gann, 1989, Volume: 80, Issue:11

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Drug Resistance; Humans; Immunoglobulin Fab Fra

1989
High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation.
    Journal of chromatography, 1989, Mar-10, Volume: 465, Issue:1

    Topics: Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Humans; Leukemia; Mitoxantrone;

1989
Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
    Cancer research, 1989, Aug-15, Volume: 49, Issue:16

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance; Gen

1989
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
    Japanese journal of cancer research : Gann, 1989, Volume: 80, Issue:10

    Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Dauno

1989
[Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:12

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluat

1989
Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine;

1989
[Intermediate-dose cytosine arabinoside in combination with mitoxantrone in the treatment of refractory leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1988, Volume: 29, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; M

1988
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
    Annals of the New York Academy of Sciences, 1987, Volume: 511

    Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma

1987
Mitoxantrone.
    The Medical letter on drugs and therapeutics, 1988, Jul-01, Volume: 30, Issue:769

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytarabine; Daunoru

1988
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
    Medical and pediatric oncology, 1988, Volume: 16, Issue:3

    Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Resistance; Hema

1988
[Cardiotoxicity of mitoxantrone].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:10

    Topics: Adolescent; Adult; Aged; Blast Crisis; Child; Doxorubicin; Electrocardiography; Female; Heart; Heart

1986
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:10

    Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Blast Crisis; Child; Daunorubicin; Drug Evaluat

1986
Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells.
    British journal of haematology, 1987, Volume: 65, Issue:1

    Topics: Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Humans; Leukemia; Leukemia, Myeloid, Acute; Lym

1987
Mitoxantrone in the treatment of acute leukemia.
    Investigational new drugs, 1987, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; Infant; Kidney Function Tests; Leu

1987
High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.
    Seminars in oncology, 1987, Volume: 14, Issue:2 Suppl 1

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Rela

1987
High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection.
    Journal of chromatography, 1987, Sep-04, Volume: 420, Issue:1

    Topics: Chromatography, High Pressure Liquid; Electrochemistry; Humans; Leukemia; Mitoxantrone; Temperature

1987
Prolonged disease-free survival in refractory acute nonlymphocytic leukemia using mitoxantrone.
    Leukemia, 1987, Volume: 1, Issue:11

    Topics: Follow-Up Studies; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Remission Induction

1987
[Phase II study of mitoxantrone in patients with acute leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Drug Administr

1986
[A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; In

1986
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:5

    Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine;

1986
Mitozantrone.
    Drug and therapeutics bulletin, 1986, Sep-08, Volume: 24, Issue:18

    Topics: Breast Neoplasms; Humans; Leukemia; Liver Neoplasms; Lymphoma; Mitoxantrone; Neoplasms

1986
Phase I-II trial of mitoxantrone in acute leukemia.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem

1985
Phase I trial of mitoxantrone in children.
    Cancer treatment reports, 1985, Volume: 69, Issue:4

    Topics: Acute Disease; Adolescent; Agranulocytosis; Anthraquinones; Child; Child, Preschool; Dose-Response R

1985
A phase II study of mitoxantrone in acute leukemia.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Alanine Transaminase; Anthraquinones; Antineoplastic

1985
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow

1985
Phase I-II trial of mitoxantrone in acute leukemia: an interim report.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Digestive System; Drug Evaluation

1985
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
    Onkologie, 1985, Volume: 8, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Female; Humans

1985
[Mitoxantrone--a new cytostatic agent].
    Fortschritte der Medizin, 1985, Feb-28, Volume: 103, Issue:8

    Topics: Acute Disease; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Leukemia; Mi

1985
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Child; D

1985
Mitoxantrone in refractory acute leukemia in children: a phase I study.
    Investigational new drugs, 1985, Volume: 3, Issue:2

    Topics: Acute Disease; Adolescent; Alopecia; Anthraquinones; Antineoplastic Agents; Child; Child, Preschool;

1985